×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 8: Environmental Impact (IND and NDA)
Session Chair(s)
Albert S. Yehaskel, MBA
President and CEO
Refuah Global Pharmaceutical Development, Inc., United States
- Categorical Exclusions
- Contents of a Categorical Exclusion Claim
- Environmental Assessments
Have an account?